{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:36:13Z","timestamp":1740184573892,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Fakult\u00e4t Heidelberg der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Die Uveitis f\u00fchrt in Industrienationen in 10\u201315\u202f% der F\u00e4lle zur Erblindung. Die Pr\u00e4valenz variiert je nach Literatur von 9 bis 730 F\u00e4llen pro 100.000 Einwohner. Lokale und systemische Steroidanwendungen stellen neben Therapien mit Immunmodulatoren die Hauptbehandlungsoptionen dar. Bei chronischer und refrakt\u00e4rer Uveitis, aber insbesondere auch bei Manifestation eines uveitischen Makula\u00f6dems k\u00f6nnen intravitreale Kortikosteroide dazu beitragen, dass die systemische immunmodulative Therapie mit krankheitsmodifizierenden antirheumatischen Medikamenten (\u201edisease modifying anti-rheumatic drugs\u201c [DMARDS]), Biologika oder Kortikosteroiden reduziert oder ersetzt wird.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ziel der Arbeit<\/jats:title>\n                <jats:p>In diesem \u00dcbersichtsartikel werden die 3\u00a0g\u00e4ngigen, injizierbaren, intravitrealen Kortikosteroidimplantate, die zur Behandlung der nichtinfekti\u00f6sen Uveitis eingesetzt werden, vorgestellt. Die Indikation, Effektivit\u00e4t und das Nebenwirkungsprofil werden im Rahmen einer Darstellung der aktuellen Literatur er\u00f6rtert. Es wurden 6\u00a0randomisierte, kontrollierte Studien zu FAc- und DEX-Implantaten mit &gt;\u202f100 Studienpatienten sowie eine Subgruppenanalyse aus einer multizentrischen, randomisierten kontrollierten Studie mit 315 Patienten gefunden und ihre Ergebnisse dargestellt.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Schlussfolgerung<\/jats:title>\n                <jats:p>Die Effektivit\u00e4t und das Sicherheitsprofil von intravitrealen Kortikosteroiden bei uveitischem Makula\u00f6dem wurden in den vergangenen Jahren in mehreren Studien untersucht und mit bestehenden Therapieformen, wie z.\u202fB. systemischer Therapie, verglichen. Durch lang wirksame Kortikosteroidimplantate l\u00e4sst sich das rezidivfreie Intervall verl\u00e4ngern, und die Anzahl der Rezidive wird reduziert. Kurz wirksame Kortikosteroid(KS)-Implantate k\u00f6nnen auch w\u00e4hrend eines Schubes eingesetzt werden. Das KS-typische Nebenwirkungsprofil ist in der Regel beherrschbar, sollte jedoch v.\u00a0a. bei phaken und\/oder jungen Patienten ber\u00fccksichtigt und ausf\u00fchrlich besprochen werden (z.\u202fB. die vorzeitige Entwicklung einer Linsentr\u00fcbung), da in der Regel eine l\u00e4ngerfristige Therapie n\u00f6tig ist.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00347-024-02096-4","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T10:02:17Z","timestamp":1723716137000},"page":"726-736","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Implantierbare intravitreale Kortikosteroide bei chronischer nichtinfekti\u00f6ser Uveitis","Implantable intravitreal corticosteroids in chronic noninfectious uveitis"],"prefix":"10.1007","volume":"121","author":[{"given":"L. J.","family":"Kessler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Naujokaitis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Auffarth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6237-7773","authenticated-orcid":false,"given":"Ramin","family":"Khoramnia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"key":"2096_CR1","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2023.04.011","volume":"130","author":"NR Acharya","year":"2023","unstructured":"Acharya\u00a0NR, Vitale\u00a0AT, Sugar\u00a0EA et\u00a0al (2023) Intravitreal Therapy for Uveitic Macular Edema&#x2014;Ranibizumab versus Methotrexate versus the Dexamethasone Implant: The MERIT Trial Results. Ophthalmology 130:914\u2013923","journal-title":"Ophthalmology"},{"issue":"2499","key":"2096_CR2","first-page":"F0225-2499","volume":"63","author":"YC Akduman","year":"2022","unstructured":"Akduman\u00a0YC, Grodsky\u00a0JD, Rodrigues\u00a0EB (2022) Comparison of Concomitant Administration of Dexamethasone in One Eye versus Fluocinolone Acetonide in the Fellow Eye in Patients with Similar Degrees of Diabetic Macular Edema. Investig Ophthalmol Vis Sci 63(2499):F0225-2499\u2013F225","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2096_CR3","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1177\/1120672119834474","volume":"30","author":"AJ Augustin","year":"2020","unstructured":"Augustin\u00a0AJ, Bopp\u00a0S, Fechner\u00a0M et\u00a0al (2020) Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN((R)) (0.19\u202fmg fluocinolone acetonide implant). Eur J Ophthalmol 30:382\u2013391","journal-title":"Eur J Ophthalmol"},{"key":"2096_CR4","doi-asserted-by":"crossref","unstructured":"Augustin AJ, Bopp S, Fechner M et\u00a0al (2021) The impact of vitrectomy on outcomes achieved with 0.19\u202fmg fluocinolone acetonide implant in patients with diabetic macular edema. Eur J Ophthalmol 11206721211014728:","DOI":"10.1177\/11206721211014728"},{"key":"2096_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40123-021-00426-2","volume":"11","author":"M Battista","year":"2022","unstructured":"Battista\u00a0M, Starace\u00a0V, Cicinelli\u00a0MV et\u00a0al (2022) Efficacy of 0.19\u202fmg Fluocinolone Acetonide Implant in Non-infectious Posterior Uveitis Evaluated as Area Under the Curve. Ophthalmol Ther 11:215\u2013224","journal-title":"Ophthalmol Ther"},{"key":"2096_CR6","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1001\/jamaophthalmol.2018.3939","volume":"136","author":"F Baudin","year":"2018","unstructured":"Baudin\u00a0F, Benzenine\u00a0E, Mariet\u00a0A\u2011S et\u00a0al (2018) Association of Acute Endophthalmitis With Intravitreal Injections of Corticosteroids or Anti\u2013Vascular Growth Factor Agents in a\u00a0Nationwide Study in France. JAMA Ophthalmol 136:1352\u20131358","journal-title":"JAMA Ophthalmol"},{"key":"2096_CR7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12348-020-00225-z","volume":"10","author":"B Bodaghi","year":"2020","unstructured":"Bodaghi\u00a0B, Nguyen\u00a0QD, Jaffe\u00a0G et\u00a0al (2020) Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye\u2014evaluating the 0.2 mug\/day fluocinolone acetonide intravitreal implant (ILUVIEN((R))). J\u00a0Ophthalmic Inflamm Infect 10:32","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"2096_CR8","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s00417-022-05893-2","volume":"261","author":"L Buhl","year":"2023","unstructured":"Buhl\u00a0L, Thurau\u00a0S, Kern\u00a0C (2023) Fluocinolone acetonide 0.19-mg implant for the treatment of noninfectious uveitis with involvement of the posterior segment: a\u00a0real-world study. Graefes Arch Clin Exp Ophthalmol 261:1101\u20131108","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2096_CR9","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1001\/archopht.126.9.1191","volume":"126","author":"DG Callanan","year":"2008","unstructured":"Callanan\u00a0DG, Jaffe\u00a0GJ, Martin\u00a0DF et\u00a0al (2008) Treatment of posterior uveitis with a\u00a0fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 126:1191\u20131201","journal-title":"Arch Ophthalmol"},{"key":"2096_CR10","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ophtha.2012.09.014","volume":"120","author":"PA Campochiaro","year":"2013","unstructured":"Campochiaro\u00a0PA, Nguyen\u00a0QD, Hafiz\u00a0G et\u00a0al (2013) Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology 120:583\u2013587","journal-title":"Ophthalmology"},{"key":"2096_CR11","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.1167\/iovs.10-6387","volume":"52","author":"JE Chang-Lin","year":"2011","unstructured":"Chang-Lin\u00a0JE, Burke\u00a0JA, Peng\u00a0Q et\u00a0al (2011) Pharmacokinetics of a\u00a0sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci 52:4605\u20134609","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2096_CR12","first-page":"317","volume":"6","author":"N Haghjou","year":"2011","unstructured":"Haghjou\u00a0N, Soheilian\u00a0M, Abdekhodaie\u00a0MJ (2011) Sustained release intraocular drug delivery devices for treatment of uveitis. J\u00a0Ophthalmic Vis Res 6:317\u2013329","journal-title":"J Ophthalmic Vis Res"},{"issue":"17","key":"2096_CR13","first-page":"3966","volume":"10","author":"M Hikal","year":"2021","unstructured":"Hikal M, Celik N, Auffarth GU et al (2021) Intravitreal 0.19\u202fmg Fluocinolone Acetonide Implant in Non-Infectious Uveitis. J\u00a0Clin Med 10(17):3966","journal-title":"J\u00a0Clin Med"},{"key":"2096_CR14","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/S0161-6420(00)00466-8","volume":"107","author":"GJ Jaffe","year":"2000","unstructured":"Jaffe\u00a0GJ, Ben-Nun\u00a0J, Guo\u00a0H et\u00a0al (2000) Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology 107:2024\u20132033","journal-title":"Ophthalmology"},{"key":"2096_CR15","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.ophtha.2018.10.033","volume":"126","author":"GJ Jaffe","year":"2019","unstructured":"Jaffe\u00a0GJ, Foster\u00a0CS, Pavesio\u00a0CE et\u00a0al (2019) Effect of an Injectable Fluocinolone Acetonide Insert on Recurrence Rates in Chronic Noninfectious Uveitis Affecting the Posterior Segment: Twelve-Month Results. Ophthalmology 126:601\u2013610","journal-title":"Ophthalmology"},{"key":"2096_CR16","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/j.ophtha.2011.07.027","volume":"118","author":"JH Kempen","year":"2011","unstructured":"Kempen\u00a0JH, Altaweel\u00a0MM, Holbrook\u00a0JT et\u00a0al (2011) Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology 118:1916\u20131926","journal-title":"Ophthalmology"},{"key":"2096_CR17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1089\/jop.2023.0027","volume":"39","author":"LJ Kessler","year":"2023","unstructured":"Kessler\u00a0LJ, Auffarth\u00a0GU, Khoramnia\u00a0R (2023) Functional and Morphological Responses to Fluocinolone Acetonide 0.19\u202fmg in Noninfectious Uveitic Macular Edema Evaluated as the Area-Under-the-Curve. J\u00a0Ocul Pharmacol Ther 39:449\u2013455","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"2096_CR18","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3390\/pharmaceutics14040688","volume":"14","author":"LJ Kessler","year":"2022","unstructured":"Kessler LJ, Labuz G, Auffarth GU, Khoramnia R (2022) Biomarkers to Predict the Success of Treatment with the Intravitreal 0.19\u202fmg Fluocinolone Acetonide Implant in Uveitic Macular Edema. Pharmaceutics 14(4):688","journal-title":"Pharmaceutics"},{"key":"2096_CR19","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1136\/bjo-2022-321415","volume":"107","author":"R Khoramnia","year":"2023","unstructured":"Khoramnia\u00a0R, Peto\u00a0T, Koch\u00a0F et\u00a0al (2023) Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): 3\u2011year results from the European IRISS registry study. Br J Ophthalmol 107:1502\u20131508","journal-title":"Br J Ophthalmol"},{"key":"2096_CR20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1001\/archopht.1992.01080140115038","volume":"110","author":"HW Kwak","year":"1992","unstructured":"Kwak\u00a0HW, D\u2019amico\u00a0DJ (1992) Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol 110:259\u2013266","journal-title":"Arch Ophthalmol"},{"key":"2096_CR21","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1001\/archophthalmol.2010.339","volume":"129","author":"C Lowder","year":"2011","unstructured":"Lowder\u00a0C, Belfort\u00a0R Jr., Lightman\u00a0S et\u00a0al (2011) Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 129:545\u2013553","journal-title":"Arch Ophthalmol"},{"key":"2096_CR22","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.ophtha.2009.11.027","volume":"117","author":"C Pavesio","year":"2010","unstructured":"Pavesio\u00a0C, Zierhut\u00a0M, Bairi\u00a0K et\u00a0al (2010) Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology 117:567\u2013575 (575.e561)","journal-title":"Ophthalmology"},{"key":"2096_CR23","first-page":"CD010469","volume":"8","author":"A Reddy","year":"2023","unstructured":"Reddy\u00a0A, Liu\u00a0SH, Brady\u00a0CJ et\u00a0al (2023) Corticosteroid implants for chronic non-infectious uveitis. Cochrane Database Syst Rev 8:CD10469","journal-title":"Cochrane Database Syst Rev"},{"key":"2096_CR24","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1097\/IAE.0000000000003080","volume":"41","author":"A Rezkallah","year":"2021","unstructured":"Rezkallah\u00a0A, Mathis\u00a0T, Abukhashabah\u00a0A et\u00a0al (2021) Long-Term Incidence And Risk Factors Of Ocular Hypertension Following Dexamethasone-Implant Injections: The Safodex\u20112 Study. Retina 41:1438\u20131445","journal-title":"Retina"},{"key":"2096_CR25","first-page":"265","volume":"11","author":"P Singh","year":"2018","unstructured":"Singh\u00a0P, Chedid\u00a0A, Deuchler\u00a0SK et\u00a0al (2018) The efficacy and safety outcomes of the 0.19\u202fmg fluocinolone acetonide implant after prior treatment with the 0.7\u202fmg dexamethasone implant in patients with diabetic macular edema. Int Med Case Rep\u00a0J 11:265\u2013269","journal-title":"Int Med Case Rep J"},{"key":"2096_CR26","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ophtha.2018.08.021","volume":"126","author":"JE Thorne","year":"2019","unstructured":"Thorne\u00a0JE, Sugar\u00a0EA, Holbrook\u00a0JT et\u00a0al (2019) Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial. Ophthalmology 126:283\u2013295","journal-title":"Ophthalmology"},{"key":"2096_CR27","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1016\/j.ophtha.2015.07.005","volume":"122","author":"BL Vanderbeek","year":"2015","unstructured":"Vanderbeek\u00a0BL, Bonaffini\u00a0SG, Ma\u00a0L (2015) The Association between Intravitreal Steroids and Post-Injection Endophthalmitis Rates. Ophthalmology 122:2311\u20132315.e2311","journal-title":"Ophthalmology"},{"key":"2096_CR28","doi-asserted-by":"publisher","first-page":"8882539","DOI":"10.1155\/2021\/8882539","volume":"2021","author":"JK Wang","year":"2021","unstructured":"Wang\u00a0JK, Huang\u00a0TL, Chang\u00a0PY et\u00a0al (2021) Comparison of Intravitreal Dexamethasone Implant and Ranibizumab in Vitrectomized Eyes with Diabetic Macular Edema. J\u00a0Ophthalmol 2021:8882539","journal-title":"J Ophthalmol"},{"issue":"1","key":"2096_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12348-019-0168-9","volume":"9","author":"LF Weber","year":"2019","unstructured":"Weber\u00a0LF, Marx\u00a0S, Auffarth\u00a0GU et\u00a0al (2019) Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema. J\u00a0Ophthalmic Inflamm Infect 9(1):3","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"2096_CR30","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.ajo.2008.12.033","volume":"147","author":"GA Williams","year":"2009","unstructured":"Williams\u00a0GA, Haller\u00a0JA, Kuppermann\u00a0BD et\u00a0al (2009) Dexamethasone Posterior-Segment Drug Delivery System in the Treatment of Macular Edema Resulting from Uveitis or Irvine-Gass Syndrome. Am J Ophthalmol 147:1048\u20131054.e1042","journal-title":"Am J Ophthalmol"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-024-02096-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-024-02096-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-024-02096-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T09:04:41Z","timestamp":1724922281000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-024-02096-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["2096"],"URL":"https:\/\/doi.org\/10.1007\/s00347-024-02096-4","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"type":"print","value":"2731-720X"},{"type":"electronic","value":"2731-7218"}],"subject":[],"published":{"date-parts":[[2024,8,15]]},"assertion":[{"value":"28 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"R.\u00a0Khoramnia gibt Forschungst\u00e4tigkeit bei der Firma Alimera sowie Referentent\u00e4tigkeit bei den Firmen Alimera und AbbVie an. L.J.\u00a0Kessler, M.\u00a0Albrecht, T.\u00a0Naujokaitis und G.\u00a0Auffarth geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}